Chemotherapy with a weekly administration of docetaxel for metastatic Hormone Refractory Prostate Cancer (HRPC). Evaluation of tolerance, Quality of Life (QOL), and clinical benefit
Gwenaelle Gravis, Frank Bladou, Naji Salem, Geneviève Macquar, Gérard Serment, Jacques Camerlo, Dominique Maranin, Patrice ViensVolume:
1
Year:
2002
Language:
english
DOI:
10.1016/s1569-9056(02)80617-0
File:
PDF, 182 KB
english, 2002